Retatrutide vs Slu-Pp-332: Comparing the Indexed Record
Where Retatrutide and Slu-Pp-332 overlap in the literature, and where they do not, is the substance of this reference.
Compound profiles
Retatrutide in the indexed record
Indexed output for Retatrutide stands at 180 records, a moderate literature, alongside 34 registered studies on ClinicalTrials.gov.
Journals represented in the current index include Nat Med.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial — Nat Med, 2024. PMID: 38858523
Slu-Pp-332 in the indexed record
The literature on Slu-Pp-332 is a limited body of work: 10 PubMed-indexed records with no registered studies currently listed on ClinicalTrials.gov.
Recent indexed work appears in ACS Chem Biol, Circulation, Int J Biol Macromol, spanning 2023–2026.
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome — J Pharmacol Exp Ther, 2024. PMID: 37739806
- Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function — Circulation, 2024. PMID: 37961903
- In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential — Rapid Commun Mass Spectrom, 2026. PMID: 41588687
- Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling — Int J Biol Macromol, 2026. PMID: 41850449
How the literature differs
The indexed record is not symmetrical between these two compounds. Retatrutide carries 170 more indexed records than Slu-Pp-332, which means published methodology, characterisation data and replication attempts are more readily located for Retatrutide. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (34 vs 0) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Side-by-side research profile
| Parameter | Retatrutide | Slu-Pp-332 |
|---|---|---|
| PubMed indexed records | 180 | 10 |
| Registered studies (ClinicalTrials.gov) | 34 | 0 |
| Literature depth | Moderate | Emerging |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
Retatrutide and Slu-Pp-332 sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Retatrutide describes conditions validated for Retatrutide: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Slu-Pp-332 without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Selecting between them for a study design
Retatrutide and Slu-Pp-332 are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Retatrutide) generally offers more methodological precedent.
Laboratory handling
Both compounds ship as lyophilised powder. Convention is storage of the sealed vial at -20°C away from light, with reconstitution immediately before experimental use. In solution, peptides are materially less stable than in lyophilised form.
Freeze-thaw cycling degrades integrity; aliquoting after reconstitution avoids repeatedly cycling one vial.
Frequently asked questions
Are Retatrutide and Slu-Pp-332 the same compound?
No. They are structurally distinct research compounds with separate literature records — 180 indexed records for Retatrutide and 10 for Slu-Pp-332.
Which of Retatrutide or Slu-Pp-332 has more published research?
Retatrutide, with 180 indexed PubMed records against 10.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Related references
- Retatrutide — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.